Reviewing PhaseBio Pharmaceuticals Inc. (PHAS)’s and Spark Therapeutics Inc. (NASDAQ:ONCE)’s results

PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and Spark Therapeutics Inc. (NASDAQ:ONCE), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PhaseBio Pharmaceuticals Inc. 9 160.80 N/A 4.52 1.73
Spark Therapeutics Inc. 99 65.42 N/A -2.36 0.00

Table 1 highlights PhaseBio Pharmaceuticals Inc. and Spark Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has PhaseBio Pharmaceuticals Inc. and Spark Therapeutics Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
PhaseBio Pharmaceuticals Inc. 0.00% 0% 0%
Spark Therapeutics Inc. 0.00% -16.7% -11%

Liquidity

PhaseBio Pharmaceuticals Inc. has a Current Ratio of 14.2 and a Quick Ratio of 14.2. Competitively, Spark Therapeutics Inc.’s Current Ratio is 5.9 and has 5.6 Quick Ratio. PhaseBio Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Spark Therapeutics Inc.

Analyst Ratings

The table delivered features the ratings and recommendations for PhaseBio Pharmaceuticals Inc. and Spark Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
PhaseBio Pharmaceuticals Inc. 0 0 0 0.00
Spark Therapeutics Inc. 0 10 1 2.09

Meanwhile, Spark Therapeutics Inc.’s consensus price target is $95.79, while its potential downside is -3.07%.

Insider & Institutional Ownership

The shares of both PhaseBio Pharmaceuticals Inc. and Spark Therapeutics Inc. are owned by institutional investors at 57.7% and 88.2% respectively. Insiders owned 0.4% of PhaseBio Pharmaceuticals Inc. shares. Insiders Comparatively, owned 7.2% of Spark Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PhaseBio Pharmaceuticals Inc. -16.74% -43.73% -40.97% 120% 0% 152.75%
Spark Therapeutics Inc. 3.31% -2.42% -5.69% 117.62% 36.68% 155.54%

For the past year PhaseBio Pharmaceuticals Inc. has weaker performance than Spark Therapeutics Inc.

Summary

On 6 of the 9 factors PhaseBio Pharmaceuticals Inc. beats Spark Therapeutics Inc.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of a form of Batten disease and Huntington's disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and SPK-LHON for treating Leber hereditary optic neuropathy, as well as preclinical programs in development for the treatment of rare genetic blinding conditions, hematologic disorders, and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.